LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

NVS

145.93

+0.38%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

NVS

145.93

+0.38%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

NVS

145.93

+0.38%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

NVS

145.93

+0.38%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

NVS

145.93

+0.38%↑

AZN

182.32

+0.05%↑

Home・Elenco Azioni・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Chiusa

13.99

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.99

Massimo

13.99

Metriche Chiave
By Trading Economics
Entrata	4.2M -23M
Dipendenti	83
EBITDA	6.6M -23M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	-4.43% downside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	418M 1B
Apertura precedente	13.99
Chiusura precedente	13.99

Ventyx Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 mar 2026, 23:12 UTC

Azioni calde

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

12 mar 2026, 22:15 UTC

Utili

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

12 mar 2026, 21:42 UTC

Principali Notizie su Eventi

Stryker Says Cyberattack Disruption Is Continuing

12 mar 2026, 21:29 UTC

Principali Notizie su Eventi

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

12 mar 2026, 21:27 UTC

Utili

Adobe CEO to Depart as AI Boosts Sales -- Update

12 mar 2026, 20:46 UTC

Utili

Adobe Posts Higher Sales With CEO Set to Depart

12 mar 2026, 20:21 UTC

Principali Notizie su Eventi

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

12 mar 2026, 23:57 UTC

Discorsi di Mercato

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

12 mar 2026, 23:38 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

12 mar 2026, 23:38 UTC

Discorsi di Mercato

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

12 mar 2026, 22:13 UTC

Utili

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

12 mar 2026, 22:13 UTC

Utili

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

12 mar 2026, 22:13 UTC

Utili

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

12 mar 2026, 22:13 UTC

Utili

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

12 mar 2026, 22:13 UTC

Utili

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

12 mar 2026, 22:13 UTC

Discorsi di Mercato

Utili

Global Equities Roundup: Market Talk

12 mar 2026, 22:13 UTC

Discorsi di Mercato

Utili

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

12 mar 2026, 21:16 UTC

Acquisizioni, Fusioni, Takeovers

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

12 mar 2026, 21:04 UTC

Utili

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

12 mar 2026, 21:02 UTC

Utili

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

12 mar 2026, 21:02 UTC

Utili

Wheaton Precious Metals 4Q Sales $865M >WPM

12 mar 2026, 21:02 UTC

Utili

Wheaton Precious Metals 4Q Net $558.3M >WPM

12 mar 2026, 21:02 UTC

Utili

Wheaton Precious Metals 4Q EPS $1.23 >WPM

12 mar 2026, 20:57 UTC

Discorsi di Mercato

Principali Notizie su Eventi

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

12 mar 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

12 mar 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

12 mar 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

12 mar 2026, 20:10 UTC

Utili

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

12 mar 2026, 20:05 UTC

Utili

Adobe 1Q Rev $6.4B >ADBE

12 mar 2026, 20:05 UTC

Utili

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Confronto tra pari

Modifica del prezzo

Ventyx Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

-4.43% in calo

Previsioni per 12 mesi

Media 13.38 USD -4.43%

Alto 14 USD

Basso 9 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Ventyx Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Ventyx Biosciences Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Chi Siamo Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.